Elevated insulin and insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean population

Journal of Korean Medical Science

Volumn 27, Issue 9, 2012, Pages 1079-1084

  Yun, Seok Joong ^a   Min, Byung Dal ^a   Kang, Ho Won ^a   Shin, Kyung Sub ^a   Kim, Tae Hwan ^b   Kim, Won Tae ^a   Lee, Sang Cheol ^a   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Glucose; HOMA IR; Insulin; Insulin resistance; Prostatic neoplasms

Indexed keywords

INSULIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; ASIAN; BLOOD; CANCER GRADING; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SOUTH KOREA;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NEOPLASM GRADING; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84866402306     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.9.1079     Document Type: Article

References (24)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-8.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Damber JE, Aus G. Prostate cancer. Lancet 2008; 371: 1710-21.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
5. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002; 3: 303-8.
6. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23: 4742-54.
7. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010; 25: 1113-21.
8. Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis 2001; 4: 101-5.
9. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 2000; 151: 541-9.
10. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989-1003.
11. Cho IC, Kwon WA, Kim JE, Joung JY, Seo HK, Chung J, Park WS, Lee KH. Prostate volume has prognostic value only in pathologic T2 radical prostatectomy specimens. J Korean Med Sci 2011; 26: 807-13.
12. Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK, Choi YH, Kim IY, Kim WJ. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci 2011; 26: 1214-8.
13. Argiles JM, Lopez-Soriano FJ. Insulin and cancer (Review). Int J Oncol 2001; 18: 683-7.
14. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001; 58: 723-8.
15. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009; 12: 259-63.
16. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-62.
17. Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, Sugawara Y, Ohmori-Matsuda K, Hozawa A, Nishino Y, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 2010; 21: 1025-32.
18. Harish K, Dharmalingam M, Himanshu M. Study Protocol: insulin and its role in cancer. BMC Endocr Disord 2007; 7: 10.
19. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007; 99: 1793-800.
20. Buschemeyer WC 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007; 52: 331-43.
21. Hsing AW, Gao YT, Chua S Jr, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 67-71.
22. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, Virtamo J. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009; 101: 1272-9.
23. Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, Hallmans G, Kaaks R, Stattin P. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007; 120: 2678-86.
24. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 2002; 87: 726-8.